The Technical AnalystExchange: CPH Sector: Healthcare Industry: Biotechnology
Novo Nordisk A/S Price, Forecast, Insider, Ratings, Fundamentals & Signals
2.01% DKK902.60
America/New_York / 30 apr 2024 @ 10:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 4 061 935 mill |
| EPS: | 18.62 |
| P/E: | 48.47 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 4 500.26 mill |
| Avg Daily Volume: | 2.73 mill |
| RATING 2024-04-30 |
|---|
| S- |
| Strong Buy |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Buy | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Buy | |
| P/E: | Buy | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 1.01x |
| Company: PE 48.47 | sector: PE 47.95 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 1.20x |
| Company: PE 48.47 | industry: PE 40.56 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
DKK892.28 (-1.14%) DKK-10.32 |
| Date: 2024-04-30 |
| Expected Trading Range (DAY) |
|---|
|
DKK 881.31 - 923.89 ( +/- 2.36%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | DKK902.60 (2.01% ) |
| Volume | 4.17 mill |
| Avg. Vol. | 2.73 mill |
| % of Avg. Vol | 152.83 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For NOVO-B.CO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
NOVO-B.CO
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.